Tag: Treatment

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) TreatmentIn a recent presentation at the European Academy of Allergy and Clinical Immunology (EAACI)...

Pharming Group Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of APDS in the European UnionLeiden, the Netherlands, May 30, 2024 - Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam:...